Aim: The study aims to develop and evaluate floating tablet formulations of ranitidine to overcome its short half-life (1.2__ampersandsignndash;1.9 hours) and maintain stable plasma drug levels. This approach seeks to enhance drug bioavailability through gastroretentive systems using rate-modifying polymers. Methodology: Nine ranitidine floating tablet formulations (F1-F9) were prepared using a multiple punch tablet compression machine with 9 mm round flat-faced punches, each containing 80 mg of ranitidine. Hydroxypropyl methylcellulose (HPMC K15M, HPMC K100M) and xanthan gum were used as rate-modifying polymers. Drug-polymer compatibility was assessed using Fourier-Transformed Infrared Spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC). The formulations were evaluated for pre-compression parameters (bulk density, tapped density, Carr__ampersandsignrsquo;s index, Hausner__ampersandsignrsquo;s ratio, angle of repose) and post-compression characteristics (hardness, friability, weight variation, drug content, swelling index, buoyancy, and in vitro drug release). Accelerated stability studies were performed for 90 days, and drug release kinetics were analyzed. Results: The floating ranitidine tablets demonstrated optimal buoyancy and extended drug release profiles. Compatibility studies confirmed no significant drug-polymer interactions. All formulations met pharmacopeial standards for physical parameters. In vitro drug release studies showed sustained drug release over several hours, and stability tests confirmed the formulations__ampersandsignrsquo; robustness. Conclusion: The developed floating tablets successfully prolonged the release of ranitidine, enhancing its half-life and maintaining steady plasma drug levels. This formulation strategy could serve as a foundation for future advancements in anti-retroviral pharmacotherapeutics, improving patient compliance and therapeutic outcomes.